Semin Respir Crit Care Med 2017; 38(04): 538-545
DOI: 10.1055/s-0037-1602383
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Solid Organ Transplantation in Sarcoidosis

J. Yserbyt1, 2, W. A. Wuyts1, 2, S. E. Verleden1, 2, G. M. Verleden1, 2, D. E. Van Raemdonck3, E. K. Verbeken4, B. M. Vanaudenaerde1, 2, R. Vos1, 2
  • 1Department of Clinical and Experimental Medicine, Lab of Respiratory Diseases, Lung Transplantation Unit, KU Leuven, Leuven, Belgium
  • 2Department of Respiratory Medicine, Lung Transplant and Respiratory Intermediate Care Unit, University Hospitals Leuven, KU Leuven, Leuven, Belgium
  • 3Department of Experimental Thoracic Surgery, Department of Thoracic Surgery, KU Leuven and University Hospitals Leuven, Leuven, Belgium
  • 4Department of Histopathology, KU Leuven, Leuven, Belgium
Further Information

Publication History

Publication Date:
27 July 2017 (online)

Abstract

Sarcoidosis is a chronic systemic inflammatory disease which is histopathologically characterized by the presence of noncaseating granulomas. When the extent of the disease is limited, without endangering the function of affected organs, clinical observation can be sufficient given that in a majority of cases, inflammation will subside with time. In more advanced sarcoidosis, especially when one or more specific organs are threatened, immunomodulatory treatment, of which steroids are the key element, over a prolonged period of time, in general, may attenuate disease activity. Treatment-refractory sarcoidosis (due to the lack of efficacy, drug toxicity or intolerability) may be progressive and, although infrequent, can result in end-stage organ failure. In these selected cases, solid organ transplantation (SOT) should be considered. In this article, SOT is positioned within the organ-specific treatment of systemic sarcoidosis and data on outcome after transplantation are discussed.